DSGN

Design Therapeutics, Inc.

Price Chart

Latest Quote

$12.44

+0.51 (+4.27%)

Current Price

Previous Close	$11.93
Open	$12.18
Day High	$12.68
Day Low	$11.94
Volume	1,036,689

Fetched: 2026-06-21T08:16:20

Stock Information

Shares Outstanding	62.46M
Total Debt	$2.73M
Cash Equivalents	$222.82M
Net Income	$-69.71M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$776.96M
EPS (TTM)	$-1.20
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$556.88M
Income	$-69.71M
Book/sh	$3.49
Cash/sh	$3.57
Employees	54

Financial Ratios

Quick Ratio	22.05
Current Ratio	22.28
Debt/Eq	1.25

Returns & Margins

ROA	-20.93%
ROE	-31.26%

Ownership

Insider Ownership	31.93%
Institutional Ownership	62.09%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-7.61
P/B	3.56

Analyst Data

Recommendation	strong_buy
Target Price	$21.00

Technical Indicators

SMA20	$10.88
SMA50	$12.33
SMA200	$9.60
RSI	72.90
ATR	0.6439

Shares Float	32.16M
Short Float	8.23%
Short Ratio	3.01
Volatility	1.66
Rel Volume	1.21

Performance History

Week	+18.14%
Month	+18.59%
Quarter	+21.25%
6 Months	+29.31%
YTD	+36.70%
Year	+238.04%
3 Years	+111.21%
5 Years	-54.08%
10 Years	-63.42%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$12.44	1,036,700
2026-06-17	$11.93	1,021,700
2026-06-16	$10.72	626,100
2026-06-15	$11.14	822,400
2026-06-12	$10.97	562,600
2026-06-11	$10.53	696,600
2026-06-10	$10.66	614,700
2026-06-09	$10.55	466,600
2026-06-08	$10.46	700,100
2026-06-05	$10.65	791,300
2026-06-04	$10.76	388,400
2026-06-03	$10.44	633,600
2026-06-02	$10.17	1,052,600
2026-06-01	$10.44	1,522,300
2026-05-29	$10.48	1,595,100
2026-05-28	$10.74	625,200
2026-05-27	$11.10	842,700
2026-05-26	$11.40	1,035,800
2026-05-22	$10.97	1,040,800
2026-05-21	$11.01	1,127,500
2026-05-20	$11.10	2,502,100
2026-05-19	$10.49	2,165,400

About Design Therapeutics, Inc.

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

📰 Latest News

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Zacks • 2026-06-09T13:40:03Z

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

Investor's Business Daily • 2026-05-18T20:07:58Z

Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN)

InvestorsHub • 2026-05-18T14:02:53Z

Jim Cramer on Design Therapeutics: “Pure Spec, Pure Spec”

Insider Monkey • 2026-05-17T13:12:44Z

Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know

Zacks • 2026-05-11T16:00:06Z

Design Therapeutics Inc (DSGN) Q1 2026 Earnings Call Highlights: Promising Progress in ...

GuruFocus.com • 2026-04-29T23:00:25Z

Design Therapeutics Q1 Earnings Call Highlights

MarketBeat • 2026-04-29T09:04:37Z

We Think Design Therapeutics (NASDAQ:DSGN) Can Afford To Drive Business Growth

Simply Wall St. • 2026-04-11T14:05:15Z

Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program

MarketBeat • 2026-03-15T13:39:21Z

Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference

MarketBeat • 2026-02-26T10:53:07Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$79,467,000	$62,383,000	$78,190,000	$67,593,000
Net Non Operating Interest Income Expense	$9,675,000	$12,795,000	$11,328,000	-
Operating Expense	$79,467,000	$62,383,000	$78,190,000	$67,593,000
General And Administrative Expense	$20,338,000	$18,033,000	$21,127,000	$18,980,000
Other Income Expense	-	-	$11,328,000	$4,285,000
Other Non Operating Income Expenses	-	-	$11,328,000	$4,285,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-69,792,000	$-49,588,000	$-66,862,000	$-63,308,000
Net Interest Income	$9,675,000	$12,795,000	$11,328,000	-
Interest Income	$9,675,000	$12,795,000	$11,328,000	-
Normalized Income	$-69,792,000	$-49,588,000	$-66,862,000	$-63,308,000
Net Income From Continuing And Discontinued Operation	$-69,792,000	$-49,588,000	$-66,862,000	$-63,308,000
Total Operating Income As Reported	$-79,467,000	$-62,383,000	$-78,190,000	$-67,593,000
Net Income Common Stockholders	$-69,792,000	$-49,588,000	$-66,862,000	$-63,308,000
Net Income	$-69,792,000	$-49,588,000	$-66,862,000	$-63,308,000
Net Income Including Noncontrolling Interests	$-69,792,000	$-49,588,000	$-66,862,000	$-63,308,000
Net Income Continuous Operations	$-69,792,000	$-49,588,000	$-66,862,000	$-63,308,000
Pretax Income	$-69,792,000	$-49,588,000	$-66,862,000	$-63,308,000
Interest Income Non Operating	$9,675,000	$12,795,000	$11,328,000	-
Operating Income	$-79,467,000	$-62,383,000	$-78,190,000	$-67,593,000
Per Share
Diluted EPS	$-1.22	$-0.88	$-1.19	$-1.14
Basic EPS	$-1.22	$-0.88	$-1.19	$-1.14
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-78,845,000	$-61,787,000	$-77,653,000	$-67,187,000
Reconciled Depreciation	$622,000	$596,000	$537,000	$406,000
EBITDA (Bullshit earnings)	$-78,845,000	$-61,787,000	$-77,653,000	$-67,187,000
EBIT	$-79,467,000	$-62,383,000	$-78,190,000	$-67,593,000
Diluted Average Shares	$57,330,192	$56,587,142	$55,984,670	$55,707,517
Basic Average Shares	$57,330,192	$56,587,142	$55,984,670	$55,707,517
Diluted NI Availto Com Stockholders	$-69,792,000	$-49,588,000	$-66,862,000	$-63,308,000
Research And Development	$59,129,000	$44,350,000	$57,063,000	$48,613,000
Selling General And Administration	$20,338,000	$18,033,000	$21,127,000	$18,980,000
Other Gand A	$20,338,000	$18,033,000	$21,127,000	$18,980,000

Fetched: 2026-06-21

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$212,503,000	$242,097,000	$277,687,000	$327,310,000
Total Assets	$226,203,000	$252,093,000	$289,643,000	$341,137,000
Total Non Current Assets	$2,419,000	$4,053,000	$5,059,000	$6,018,000
Current Assets	$223,784,000	$248,040,000	$284,584,000	$335,119,000
Prepaid Assets	$2,262,000	$1,300,000	$1,354,000	$3,617,000
Receivables	$1,677,000	$1,263,000	$1,432,000	$1,115,000
Accrued Interest Receivable	$1,677,000	$1,263,000	$1,432,000	$1,115,000
Cash Cash Equivalents And Short Term Investments	$219,845,000	$245,477,000	$281,798,000	$330,387,000
Cash And Cash Equivalents	$16,856,000	$22,563,000	$21,200,000	$26,500,000
Other Non Current Assets	-	$427,000	$430,000	$459,000
Non Current Deferred Assets	-	-	-	-
Other Current Assets	-	-	-	-
Debt
Total Debt	$1,535,000	$2,334,000	$3,050,000	$3,691,000
Long Term Debt And Capital Lease Obligation	$645,000	$1,534,000	$2,334,000	$3,051,000
Current Debt And Capital Lease Obligation	$890,000	$800,000	$716,000	$640,000
Liabilities
Total Liabilities Net Minority Interest	$13,700,000	$9,996,000	$11,956,000	$13,827,000
Total Non Current Liabilities Net Minority Interest	$645,000	$1,534,000	$2,334,000	$3,051,000
Current Liabilities	$13,055,000	$8,462,000	$9,622,000	$10,776,000
Payables And Accrued Expenses	$7,534,000	$4,086,000	$4,872,000	$6,593,000
Payables	$2,312,000	$2,186,000	$1,940,000	$3,025,000
Accounts Payable	$2,312,000	$2,186,000	$1,940,000	$3,025,000
Equity
Common Stock Equity	$212,503,000	$242,097,000	$277,687,000	$327,310,000
Total Equity Gross Minority Interest	$212,503,000	$242,097,000	$277,687,000	$327,310,000
Stockholders Equity	$212,503,000	$242,097,000	$277,687,000	$327,310,000
Gains Losses Not Affecting Retained Earnings	$403,000	$475,000	$62,000	$-3,356,000
Other Equity Adjustments	$403,000	$475,000	$62,000	$-3,356,000
Retained Earnings	$-297,006,000	$-227,214,000	$-177,626,000	$-110,764,000
Preferred Securities Outside Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$60,398,051	$56,754,341	$56,473,598	$55,895,596
Share Issued	$60,398,051	$56,754,341	$56,473,598	$55,895,596
Tangible Book Value	$212,503,000	$242,097,000	$277,687,000	$327,310,000
Invested Capital	$212,503,000	$242,097,000	$277,687,000	$327,310,000
Working Capital	$210,729,000	$239,578,000	$274,962,000	$324,343,000
Capital Lease Obligations	$1,535,000	$2,334,000	$3,050,000	$3,691,000
Total Capitalization	$212,503,000	$242,097,000	$277,687,000	$327,310,000
Additional Paid In Capital	$509,100,000	$468,830,000	$455,245,000	$441,424,000
Capital Stock	$6,000	$6,000	$6,000	$6,000
Common Stock	$6,000	$6,000	$6,000	$6,000
Long Term Capital Lease Obligation	$645,000	$1,534,000	$2,334,000	$3,051,000
Current Capital Lease Obligation	$890,000	$800,000	$716,000	$640,000
Pensionand Other Post Retirement Benefit Plans Current	$4,631,000	$3,576,000	$4,034,000	$3,543,000
Current Accrued Expenses	$5,222,000	$1,900,000	$2,932,000	$3,568,000
Net PPE	$2,419,000	$3,626,000	$4,629,000	$5,559,000
Accumulated Depreciation	$-2,264,000	$-1,655,000	$-1,059,000	$-522,000
Gross PPE	$4,683,000	$5,281,000	$5,688,000	$6,081,000
Leases	$172,000	$151,000	$151,000	$151,000
Other Properties	$3,888,000	$4,507,000	$4,914,000	$5,307,000
Machinery Furniture Equipment	$623,000	$623,000	$623,000	$623,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$202,989,000	$222,914,000	$260,598,000	$303,887,000
Construction In Progress	-	-	$0	$0

Fetched: 2026-06-21

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-54,551,000	$-43,445,000	$-58,816,000	$-52,235,000
Operating Activities
Operating Cash Flow	$-54,358,000	$-43,105,000	$-58,560,000	$-51,317,000
Cash Flow From Continuing Operating Activities	$-54,358,000	$-43,105,000	$-58,560,000	$-51,317,000
Investing Activities
Capital Expenditure	$-193,000	$-340,000	$-256,000	$-918,000
Investing Cash Flow	$22,913,000	$43,955,000	$52,536,000	$-220,987,000
Cash Flow From Continuing Investing Activities	$22,913,000	$43,955,000	$52,536,000	$-220,987,000
Net Other Investing Changes	-	-	-	$39,000
Financing Activities
Issuance Of Capital Stock	$24,847,000	$0	-	$0
Financing Cash Flow	$25,738,000	$513,000	$724,000	$235,000
Cash Flow From Continuing Financing Activities	$25,738,000	$513,000	$724,000	$235,000
Net Common Stock Issuance	$24,847,000	$0	-	$0
Common Stock Issuance	$24,847,000	$0	-	$0
Net Other Financing Charges	-	-	-	$-427,000
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
End Cash Position	$16,856,000	$22,563,000	$21,200,000	$26,500,000
Beginning Cash Position	$22,563,000	$21,200,000	$26,500,000	$298,569,000
Changes In Cash	$-5,707,000	$1,363,000	$-5,300,000	$-272,069,000
Proceeds From Stock Option Exercised	$891,000	$513,000	$724,000	$662,000
Net Investment Purchase And Sale	$23,106,000	$44,295,000	$52,792,000	$-220,108,000
Sale Of Investment	$314,885,000	$274,470,000	$277,495,000	$92,890,000
Purchase Of Investment	$-291,779,000	$-230,175,000	$-224,703,000	$-312,998,000
Net PPE Purchase And Sale	$-193,000	$-340,000	$-256,000	$-918,000
Purchase Of PPE	$-193,000	$-340,000	$-256,000	$-918,000
Change In Working Capital	$3,110,000	$-993,000	$728,000	$1,992,000
Change In Payables And Accrued Expense	$4,486,000	$-1,219,000	$-1,246,000	$5,385,000
Change In Payable	$4,486,000	$-1,219,000	$-1,246,000	$5,385,000
Change In Account Payable	$4,486,000	$-1,219,000	$-1,246,000	$5,385,000
Change In Prepaid Assets	$-1,376,000	$226,000	$1,974,000	$-3,393,000
Other Non Cash Items	$406,000	$6,000	$33,000	$64,000
Stock Based Compensation	$14,549,000	$13,072,000	$13,088,000	$10,925,000
Amortization Of Securities	$-3,253,000	$-6,198,000	$-6,084,000	$-1,396,000
Depreciation Amortization Depletion	$622,000	$596,000	$537,000	$406,000
Depreciation And Amortization	$622,000	$596,000	$537,000	$406,000
Depreciation	$622,000	$596,000	$537,000	$406,000
Net Income From Continuing Operations	$-69,792,000	$-49,588,000	$-66,862,000	$-63,308,000
Repayment Of Debt	-	-	-	-
Issuance Of Debt	-	-	-	-
Interest Paid Supplemental Data	-	-	-	-
Net Issuance Payments Of Debt	-	-	-	-
Net Long Term Debt Issuance	-	-	-	-
Long Term Debt Payments	-	-	-	-
Long Term Debt Issuance	-	-	-	-
Change In Other Current Liabilities	-	-	-	-

Fetched: 2026-06-21